Meiqi Li

Dr. Meiqi Li

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2023 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
MLMeiqi Li
Meiqi Li
SYSuyan Yan
Suyan Yan
RDRongrong Dong
Rongrong Dong
WXWeizhen Xiang
Weizhen Xiang
ZMZhenzhen Ma
Zhenzhen Ma
QYQingrui Yang
Qingrui Yang

1 January 2022 in Yonsei Medical Journal
Verified
Journal Article
Open access
PDF file
QZQingfeng Zhang
Qingfeng Zhang
CMChunyan Ma
Chunyan Ma
RDRongrong Dong
Rongrong Dong
WXWeizhen Xiang
Weizhen Xiang
MLMeiqi Li
Meiqi Li
QYQingrui Yang
Qingrui Yang
Zhang Q, et al. Yonsei Med J. 2022 Feb;63(2):148-157. https://doi.org/10.3349/ymj.2022.63.2.148

20 December 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
WXWeizhen Xiang
Weizhen Xiang
RDRongrong Dong
Rongrong Dong
MLMeiqi Li
Meiqi Li
BLBaocheng Liu
Baocheng Liu
ZMZhenzhen Ma
Zhenzhen Ma
QYQingrui Yang
Qingrui Yang
Connective tissue disease (CTD) patients may suffer from pulmonary arterial hypertension (PAH), a serious complication, and anti-U1 ribonucleoprotein (RNP) antibodies can be used as a potential indicator for the development and prognosis of CTD-associated PAH (CTD-PAH). However, there are still some controversies; thus, a systematic review and meta-analysis were performed. We searched PubMed, Embase, Cochrane Library, and Scopus for eligible studies and assessed their quality using Newcastle–Ottawa scales or Agency for Healthcare Research and Quality indicators according to the type of research. Odds ratio (OR) was adopted as a measure of effect in risk factor analysis, and hazard ratio (HR) was adopted for prognostic factor analysis. Publication bias was evaluated using the Egger’s test. Thirteen studies were finally included. Anti-U1 RNP antibody was proved as a risk factor for PAH among CTD patients (OR = 5.30, 95%CI 2.96–9.48, p < 0.05) and a protective factor against mortality among CTD-PAH patients (HR = 0.55, 95%CI 0.36–0.83, p < 0.05). CTD patients with positive anti-U1 RNP antibodies are at high risk for PAH, so routine screening examinations, including echocardiography, are recommended. Additionally, anti-U1 RNP positivity has been linked to decreased mortality in patients with CTD-PAH.

1 August 2026 in Journal of Asthma and Allergy
Verified
Journal Article
Open access
PDF file
MLMeiqi Li
Meiqi Li
AZAnhao Zheng
Anhao Zheng
YLyi Liu
yi Liu
Eosinophils are key immunopathological cells in respiratory diseases and contribute to airway inflammation, tissue remodeling, and disease heterogeneity. Although eosinophils have traditionally been regarded as biomarkers of type 2 inflammation, increasing evidence indicates that they also function as active mediators of lung function impairment in selected respiratory diseases, including chronic obstructive pulmonary disease, asthma, and eosinophilic pneumonia. These disorders were selected because they represent distinct yet complementary models of eosinophil-associated airway and parenchymal injury, allowing comparison of shared and disease-specific mechanisms. Mechanistically, eosinophils impair lung function through the coordinated release of cytotoxic granule proteins, reactive oxygen species, lipid mediators, and cytokines, while interacting with epithelial, immune, and structural cells to amplify inflammation, airway remodeling, and tissue injury. These advances have improved understanding of eosinophil biology and facilitated the development of clinically relevant biomarkers and targeted therapies. Blood and sputum eosinophil counts remain the most widely used biomarkers, whereas emerging biomarkers, including eosinophil-derived neurotoxin, may further improve disease stratification and treatment monitoring. Biologics targeting interleukin-5 and its receptor have demonstrated therapeutic benefit in selected eosinophilic respiratory diseases, although treatment responses differ among disease phenotypes. This review summarizes current evidence regarding the molecular mechanisms linking eosinophils to lung function impairment, discusses the evolving role of eosinophils as both biomarkers and pathogenic drivers, and highlights the biomarker and therapeutic implications for precision management of respiratory diseases.